Quick answer: are peptides legal? It depends on the peptide and how it is sold. FDA-approved peptide drugs such as semaglutide and tirzepatide are legal with a prescription. Compounded peptides are legal only when the substance qualifies under federal compounding rules. “Research use only” peptides sold for human use are unapproved drugs, and FDA has said the label does not change that.[6] As of October 2026, peptides such as BPC-157 were in limbo: removed from FDA’s safety-risk list in April 2026 but not yet added to the list of substances pharmacies may use.[1][3]
This is our overview page. It summarizes the rules by category and links to detailed guides on each topic. For news and updates, see the FDA and peptide regulation hub.
Federal status at a glance
| Category | Examples | Legal status in the U.S. (Oct 2026) | Main law |
|---|---|---|---|
| FDA-approved peptide drugs | Semaglutide, tirzepatide, liraglutide, tesamorelin, teriparatide | Legal with a prescription for approved or off-label medical use | FD&C Act section 505 |
| Compounded peptides | Pharmacy-made versions of eligible peptides | Legal only if the substance and pharmacy meet 503A or 503B rules[1] | FD&C Act sections 503A, 503B |
| Dietary supplements | Collagen peptides and similar food ingredients | Legal as supplements, but not if the ingredient was first a drug[5] | DSHEA of 1994 |
| “Research use only” products | BPC-157, TB-500, retatrutide vials sold online | Unapproved new drugs when marketed for people[6] | FD&C Act sections 505(a), 301(d) |
| Specially restricted | Human growth hormone | Felony to distribute outside approved medical use[7] | FD&C Act section 303(e) |
The rest of this page explains each row.
FDA-approved peptide drugs
Dozens of peptides are approved medicines, from insulin and GLP-1 drugs to oxytocin, PT-141 (bremelanotide) and tesamorelin. These are legal to prescribe and dispense like any other prescription drug. Doctors can also prescribe them off-label. See our list of FDA-approved peptides and the FDA peptide regulation timeline.
Compounded peptides
Compounding pharmacies can make drugs for individual patients, but only within limits. A 503A pharmacy may use a bulk substance only if it is part of an approved drug, has a USP monograph, or is on FDA’s 503A bulks list. While FDA builds that list, it sorts nominated substances into interim categories. Category 2 means FDA believes the substance raises significant safety risks.[1]
Key 2026 events:
- April 15, 2026: FDA announced it would remove 12 peptides from Category 2 because the nominators withdrew their nominations. The change took effect after a 7-day notice period, around April 22.[2] FDA’s page, current as of April 22, 2026, now lists BPC-157, TB-500, semax, epitalon, MOTS-c, KPV, thymosin alpha-1 and others under “nominated but withdrawn.”[1]
- Still in Category 2: GHRP-2, GHRP-6, ipamorelin (for 503B), kisspeptin-10 (for 503A) and ibutamoren (MK-677), among others.[1]
- July 23–24, 2026: FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides and recommended six (BPC-157, KPV, TB-500, MOTS-c, semax and epitalon) for the 503A bulks list. It did not recommend emideltide (DSIP). The votes are not binding: FDA must still complete notice-and-comment rulemaking before pharmacies can lawfully compound them.[3]
Compounded GLP-1s follow a separate track. FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025. After grace periods ended in 2025, compounders generally may no longer make copies of these drugs.[4] See compounded tirzepatide, compounded semaglutide vs Ozempic and the GLP-1 compounding ban.
Peptides as dietary supplements
The Dietary Supplement Health and Education Act (DSHEA) of 1994 lets some ingredients be sold as supplements without FDA approval. But section 201(ff)(3)(B) of the FD&C Act excludes any article first approved as a drug, or first studied as a drug in substantial clinical investigations that were made public, unless it was sold as a supplement or food first.[5] That is why approved peptide drugs cannot be sold as supplements. Read more in DSHEA and peptide supplements and peptides and GRAS status.
“Research use only” peptides
Many peptides are sold online as “research chemicals” with “not for human consumption” labels. FDA’s position, repeated in warning letters through 2026, is that these disclaimers do not matter when the seller’s website shows the products are meant for people. In that case, they are unapproved new drugs.[6] See research use only peptides and buying peptides online: legal risks.
Controlled substances and special rules
Most peptides are not listed in the Controlled Substances Act schedules. Two exceptions are worth knowing:
- Human growth hormone. FD&C Act section 303(e) makes it a crime, punishable by up to 5 years in prison (10 if a minor is involved), to knowingly distribute hGH for any use in humans other than treating a disease or recognized condition under an approved use and a doctor’s order. DEA is authorized to investigate.[7] See our hGH profile.
- Hidden controlled drugs. Products sold as peptides or SARMs have been found to contain testosterone, a Schedule III anabolic steroid. Our guide to DEA peptide classification covers this.
Importing peptides
FDA says that in most circumstances it is illegal for individuals to import drugs for personal use. It may allow limited exceptions, generally up to a 3-month supply for a serious condition.[10] See peptide import laws and peptide legality by country.
State laws: mostly federal, with a few exceptions
Drug approval, compounding eligibility and import rules are federal, so they apply in every state. States add their own layer by licensing pharmacies, doctors and clinics, and through medical and pharmacy board rules. We list only state actions we could verify in the official record:
| State | Law or bill | Status | What it does |
|---|---|---|---|
| Louisiana | SB 253, Act 374 (2026) | Enacted; effective August 1, 2026 | Bars licensing boards from stopping prescribers from providing peptides shipped from a compliant 503B outsourcing facility or 503A pharmacy, or stopping Louisiana pharmacists from compounding peptides in compliance with 21 U.S.C. 353a and USP-NF chapters[8] |
| California | AB 2442 (2026) | Held in committee, May 14, 2026 | Would have created a state research and therapeutic access program for investigational peptides[9] |
Louisiana’s law does not override federal law. It still requires compliance with sections 503A and 503B, so a peptide that is not eligible for compounding federally is not made eligible by the state law.[8] For medical board rules on peptide clinics, see state medical boards and peptide therapy and telehealth peptide prescriptions.
Sports rules are separate
Even a legally prescribed peptide can be banned in sport. WADA’s 2026 Prohibited List names BPC-157 under S0 and TB-500, GHRPs and GHRH analogues under S2, all banned at all times.[11] See peptides and the WADA Prohibited List and peptides in professional sports.
All our regulatory guides
- FDA actions: the 2026 FDA peptide ban explained, FDA’s peptide compounding crackdown, FDA warning letters on peptides, BPC-157 legal status, GLP-1 drug shortage
- How products are regulated: 503A vs 503B compounding, peptide quality standards, peptide clinical trial regulation, peptide advertising rules, peptide patents and exclusivity
- Access and history: peptide access rights, history of peptide regulation
- Outside the U.S.: Canada peptide regulations, peptide regulation in the EU, UK and Australia
This is general information, not legal advice. Rules are changing quickly in 2026; check the date on any source and talk to a lawyer or your state board about your situation.
